Search results
Results from the WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
In other cases, imaging can be performed by labelling a suitable radionuclide to the same peptide as used for therapy. [22] Radionuclides that can be used for imaging include gallium-68, technetium-99m and fluorine-18. [21] Currently used peptides can result in high kidney doses, as the radiopharmaceutical is retained for relatively long ...
Lanreotide is the first and only FDA approved antitumor therapy demonstrating a statistically significant progression-free survival benefit in a combined population of patients with GEP-NETS. [citation needed] Other medications that block particular secretory effects can sometimes relieve symptoms. [52]
In many people with acromegaly, GH levels fall within one hour and headaches improve within minutes after the injection. Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to treat people with acromegaly caused by non-pituitary tumors. [citation needed]
Harry Jowsey MICHAEL TRAN/AFP via Getty Images Too Hot to Handle alum Harry Jowsey revealed that a dermatologist found skin cancer on his shoulder. “Hi friends, there isn’t really an easy way ...
Move over, Wordle, Connections and Mini Crossword—there's a new NYT word game in town! The New York Times' recent game, "Strands," is becoming more and more popular as another daily activity ...
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.